Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GE Healthcare Life Sciences and Promosome Sign Licensing Agreement

Published: Tuesday, April 29, 2014
Last Updated: Tuesday, April 29, 2014
Bookmark and Share
Innovative mammalian cell line development technologies that show promise for increasing manufacturing efficiency of vital biopharmaceuticals.

GE Healthcare Life Sciences and Promosome LLC have announced that the companies have signed a licensing agreement, granting GE Healthcare exclusive rights to an innovative suite of mammalian cell line development technologies, developed by Promosome, for increasing protein expression in mammalian cell culture.

Under the terms of agreement, Promosome will receive milestone payments for technology transfer and subsequent royalties upon commercialization.

Mammalian cell culture plays a key role in the manufacture of biotherapeutic proteins for the treatment of diseases such as cancer and rheumatoid arthritis, as well as the new generation of vaccines. GE Healthcare already offers a wide range of start-to-finish technologies and services for the biopharmaceutical manufacturing industry.

In-licensing of Promosome’s cell line development technologies will enable GE Healthcare Life Sciences to expand its offering with a cell-line generation service focused on delivering increased expression levels for hard-to-manufacture therapeutic proteins and improving manufacturing efficiency through increased protein yields.

Morgan Norris, General Manager for Upstream Products, BioProcess, GE Healthcare Life Sciences, said: “The biopharmaceutical industry is constantly looking for ways to improve efficiency and increase flexibility. Promosome’s technologies provide a powerful way to drive up protein yields and, more excitingly, boost the output of cell lines for hard-to-express proteins to a level where large-scale manufacturing becomes viable and previously disregarded therapies can be progressed.”

John Manzello, President and CEO of Promosome, added: “This agreement represents a significant commercial milestone for Promosome. We are excited to be working closely with the team at GE Healthcare to transfer our technology to their in-house experts. GE Healthcare is ideally positioned to deliver our technology to the global biopharmaceutical industry.”

GE Healthcare has recently acquired Thermo Fisher’s HyClone™ cell culture media and sera allowing GE to expand its offering of start-to-finish technologies for the discovery and manufacturing of innovative new medicines and vaccines. In 2012 the company launched KUBio™, an off-the-shelf modular factory for the manufacture of monoclonal antibodies.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GE Acquires Strategic Assets from Thermo
GE to acquire cell culture media and sera, gene modulation and magnetic beads businesses.
Monday, January 06, 2014
GE Healthcare to acquire Xcellerex Inc.
Addition of high growth company builds integrated, start-to-finish industry offering, focused on lowering costs, increasing productivity and reducing time to market.
Thursday, March 08, 2012
GE Healthcare Executes Recombinant Protein L License from Affitech
Company agrees to pay a royalty of the net sales of all related products to Affitech.
Tuesday, October 18, 2011
GE Healthcare to Invest $1 Billion in New Oncology Solutions
Expanding advanced cancer diagnostic and molecular imaging capabilities.
Saturday, September 17, 2011
GE Healthcare Appoints Kieran Murphy as Life Sciences CEO, Successor to Peter Ehrenheim
On 1 April 2011, Kieran Murphy will be promoted to succeed current Life Sciences President and CEO Peter Ehrenheim who will retire from GE after a transition period on July 31 2011.
Tuesday, February 22, 2011
GE Healthcare to Host DiPIA 2010 - Developments in Protein Interaction Analysis
Addressing functional characterization of proteins and their interactions.
Thursday, July 22, 2010
GE Healthcare to Host ‘Current Trends in Microcalorimetry and Biacore Symposium’
The symposium addressing functional characterization of biomolecular stability and interactions.
Monday, June 22, 2009
GE Healthcare Forms Strategic Alliance with FUJIFILM in Life Sciences
Under the alliance, Fujifilm will develop, manufacture and supply advanced biomolecular imaging systems to GE Healthcare.
Thursday, June 04, 2009
GE Healthcare Forms Strategic Alliance with FUJIFILM in Life Sciences
GE Healthcare announced that it has entered into a Strategic Alliance Agreement with FUJIFILM Corporation. Under the alliance, Fujifilm will develop, manufacture and supply advanced biomolecular imaging systems to GE Healthcare.
Thursday, May 28, 2009
Celestial Biologicals and GE Healthcare Collaborates to Set up Plasma Fractionation Facility in India
The collaboration will include technology, products, processes and project development for establishing chromatography-based plasma fractionation facility.
Friday, January 23, 2009
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Potential Target for Revolutionary Antibiotics
An international team of including the Lomonosov Moscow State University researchers discovered which enzyme enables Escherichia coli bacterium (E. coli) to breathe.
DNA Barcodes Gone Wild
A team of researchers at University of Toronto’s Donnelly Centre and Sinai Health System’s Lunenfeld-Tanenbaum Research Institute (LTRI) has developed a new technology that can stitch together DNA barcodes inside a cell to simultaneously search amongst millions of protein pairs for protein interactions.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Grant to Fund Million Peaks Project
The European Research Council (ERC) has awarded a prestigious Advanced Grant to Prof. Peter Schoenmakers, Prof. Albert Polman and Prof. Huib Bakker, all three of whom work at the University of Amsterdam (UvA).
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!